Late Immune-Related Adverse Events After At Least Two Years of Immune Checkpoint Inhibitor Therapy: Incidence and Association With Survival in Patients With Advanced NSCLC by Omar Elghawy, MD, Adam Barsouk, MD, Jonathan H. Sussman, BS, Benjamin A. Bleiberg, MD, Lauren Reed-Guy, MD, Christopher D’Avella, MD, Aditi Singh, MD, Christine Ciunci, MD, MSCE, Kyle Robinson, MD, John Kosteva, MD, Corey Langer, MD, Roger B. Cohen, MD, Charu Aggarwal, MD, MPH, Melina Marmarelis, MD, MSCE, Lova Sun, MD, MSCE

Get full text